Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Tevogen Bio HoldingsFRA:G280 10 FCF Yield % is -60.96 as of Jul. 16, 2026. GuruFocus rates FRA:G280 with a GF Score™ of 10/100. The stock has 4 warning signs investors should review. Among 1,409 Biotechnology companies, Tevogen Bio Holdings ranks worse than 84.95% on this metric.
FCF Yield % is calculated as Free Cash Flow divided by Market Capitalization. It is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.
Similar to Earnings Yield %, FCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high free cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.
Tevogen Bio Holdings FCF Yield % Related Terms
Tevogen Bio Holdings FCF Yield % Historical Data
* Premium members only.
The historical data trend for Tevogen Bio Holdings's FCF Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:G280 vs GRDX, DYAI, KYNB: FCF Yield % Comparison
For the Biotechnology subindustry, Tevogen Bio Holdings's FCF Yield %, along with its competitors' market caps and FCF Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Tevogen Bio Holdings FCF Yield % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Tevogen Bio Holdings's FCF Yield % distribution charts can be found below:
* The bar in red indicates where Tevogen Bio Holdings's FCF Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Tevogen Bio Holdings (FRA:G280) has a FCF Yield % of -60.96 as of Jul. 16, 2026. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on Tevogen Bio Holdings and its competitors. According to the industry distribution chart, Tevogen Bio Holdings ranks #1197 out of 1409 companies in the Biotechnology industry, placing it in the top 85%.
Is Tevogen Bio Holdings' FCF Yield % too high?
Tevogen Bio Holdings' current FCF Yield % is -60.96. Based on the distribution chart, Tevogen Bio Holdings ranks #1197 out of 1409 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Tevogen Bio Holdings has a GF Score™ of 10/100, reflecting its overall financial health beyond just this single metric.
How does Tevogen Bio Holdings' FCF Yield % compare to GRDX and DYAI?
According to the Biotechnology industry distribution chart, Tevogen Bio Holdings ranks #1197 out of 1409 companies for FCF Yield %. This places Tevogen Bio Holdings in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Yield % for a Biotechnology company?
A good FCF Yield % depends on the Biotechnology industry context. However, FCF Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Yield % mean?
A high FCF Yield % can signal that a stock is expensive relative to its fundamentals. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on Tevogen Bio Holdings and its competitors. Tevogen Bio Holdings's current FCF Yield % is -60.96. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Tevogen Bio Holdings stock overvalued right now?
Tevogen Bio Holdings (FRA:G280) has a current FCF Yield % of -60.96. The current FCF Yield % is -60.96. Tevogen Bio Holdings' overall GF Score™ is 10/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Yield % calculated?
FCF Yield % is calculated from a company's financial statements. For Tevogen Bio Holdings (FRA:G280), the current FCF Yield % is -60.96 as of Jul. 16, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Tevogen Bio Holdings Inc a clinical-stage specialty immunotherapy company harnessing CD8+ cytotoxic T lymphocytes (CD8+ CTLs or CTLs), to develop off-the-shelf, precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders. The first clinical product of ExacTcell, TVGN 489, is initially being developed to fill a critical gap in COVID-19 therapeutics for the immunocompromised and the high-risk elderly, with potential applications in both treatment and prevention of chronic, lingering symptoms of the disease (Long COVID). Viruses, including COVID-19, hijack cellular machinery to transform infected cells into virus production plants.
10GF Score
Get the complete analysis for FRA:G280
FCF Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:G280 has been successfully added to your 
